Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC

NCT03876587 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

79

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Pyrotinib Maleate combine with Docetaxel

Sponsor

Zhejiang Cancer Hospital

Collaborators

[object Object]